A study of 11 astronauts who spent time on the International Space Station found six had developed stagnant or reversed flow in the internal jugular vein within about 50 days, and one had developed thrombosis, according to the published paper summarised in science reporting. The authors say consequences are not yet known.
Weightlessness shifts blood and fluid toward the head, producing facial puffiness, reduced leg volume and changed stroke and plasma volumes. Cerebral venous drainage in that environment is the mechanistic concern behind the finding.
The sample is small, as astronaut studies must be, and a single thrombosis case establishes a signal to investigate, not a risk rate. Larger inference awaits more crews, imaging consistency and comparison with ground analogues.
Digital News Point reports the papers findings and caveats as published. Readers should not draw personal medical conclusions from spaceflight research.
Reporting is based on statements and reporting available at publication time. Digital News Point verified the central facts against at least two reputable sources and attributes claims to their sources in the text. This story will be updated if confirmed new information materially changes the account, and corrections will follow the site corrections policy.
The physiology behind the finding
The internal jugular veins are major drainage routes for blood leaving the brain, and on Earth they work with gravity. Upright, they are partially collapsed and drainage also uses other venous pathways; lying flat, they fill and carry more flow. Weightlessness removes the upright option entirely. From the first days in orbit, fluid that gravity would hold in the legs shifts toward the head and chest, producing the facial puffiness and reduced leg volume long documented in crew members. In that environment the jugular system operates continuously in something closer to the lying flat state, while the usual cues that vary venous pressure through the day, standing, walking, straining, are replaced by exercise sessions and the mild pressure changes of station life. Stagnant or reversed flow in that setting is therefore a coherent mechanistic concern rather than a random observation: slow or disordered venous flow is one of the classic conditions that allow clots to form, alongside vessel wall injury and changes in blood composition.
Why eleven astronauts can still produce an important signal
Space medicine routinely works with numbers that would be unusable in ordinary clinical research, because the exposed population is tiny and every additional crew member takes years to add. In that context a finding in six of eleven flyers, with one thrombosis, functions as a safety signal rather than an epidemiological estimate. It tells flight surgeons that a phenomenon they may have considered theoretical occurs in practice, that it appears within roughly the first fifty days on the timeline reported, and that surveillance is warranted. What it cannot do is assign a percentage risk to a future astronaut, compare risk between vehicles or mission lengths, or show whether flow changes resolve, persist or progress after landing. Those questions require more crews examined with the same ultrasound protocol at the same mission points, plus ground based analogues such as strict bed rest with head down tilt, which reproduces some fluid shift features and allows larger samples under controlled conditions.
What follow up looks like in practice
A mature follow up programme has several strands. Imaging consistency is the first: standardised ultrasound examinations, ideally with crew trained to acquire comparable views, so that stagnant flow means the same thing in every dataset. Timing is the second, since measurements clustered early in flight cannot describe late mission behaviour on the six month or longer expeditions relevant to Mars planning. The third strand is clinical correlation, examining whether flow findings track with symptoms, eye examinations, exercise patterns, or individual anatomy, because a finding that clusters in identifiable crew members leads to different countermeasures than one spread evenly across all flyers. Finally there is the countermeasure question itself, which ranges from operational measures that vary venous pressure during the day to medical policies that a Mars mission, with communication delays and no evacuation option, would need settled long before launch. Each strand is slower than public curiosity would like, because each requires flight opportunities.
Reading this study responsibly
The authors own caution, that consequences are not yet known, is the sentence to hold on to. A single thrombosis case in a monitored astronaut who could be assessed and managed within an established medical system is evidence for vigilance, not evidence that long missions are unsafe, just as reassuring scans in the other crew members are not evidence that the issue can be forgotten. Readers should also resist importing the finding into personal health decisions: the physiology of healthy screened astronauts in weightlessness is a poor guide to vein health on Earth. The genuine significance is institutional. Before crews commit to transits where the nearest hospital is months away, medicine has to know how cerebral venous drainage behaves across whole missions, and this small study is the reason that question is now asked with data rather than theory. Further crews, scanned consistently, will decide how large the answer looms.
